Diagnosis of Renal Cell Carcinoma on 68Ga-PSMA PET-CT and Radioligand Therapy With 177Lu-EB-PSMA-617
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Renal Cell Carcinoma (RCC) is the second most common tumor in urology. Considering its
origination from kidney, an organ with intense physiological uptake and excretion of
68Ga-PSMA, this study aims to evaluate the uptake of 68Ga-PSMA in RCC compared to 18F-FDG in
the same patients, and assess the feasibility of 177Lu-EB-PSMA-617 treatment in patients with
the advanced RCC.